Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: May 13, 2025
Company had a strong start to 2025, emerging as an R&D-focused organization
Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025
Read more at globenewswire.comNASDAQ:LXRX (7/24/2025, 9:48:58 AM)
1.2012
-0.01 (-0.73%)
Find more stocks in the Stock Screener
